对於上皮成长因子受体高度表现(EGFR-expression)的肿瘤细胞,ERBITUX有效 诱发细胞凋亡(apoptosis)、抑制血管生成因子 … tw.myblog.yahoo.com|基于2个网页 2. 高度上皮成长因子受体表现 而高度上皮成长因子受体表现(EGFR-expression)表示:。 tw.myblog.yahoo.com|基于2个网页 ...
Douillard JY,et al., Relationship Between EGFR Expression, EGFR Mutation Status, and the Ef cacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced NonCSmall-Cell Lung Cancer,J Thorac Oncol. 2014 May;9(5):717-24.
EGFR ExpressionPurpose: Although controversial, assessment of epidermal growth factor receptor (EGFR) expression is required for the approved indications of Cetuximab in metastatic colorectal cancer (mCRC). With the objective of improving patient selection, "ERBITUX-OUEST" study aimed at analyzing EGFR ...
Conclusions: High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.Similar...
Epidermal growth factor receptor (EGFR) is often overexpressed in a variety of human cancers, and its expression is associated with poor prognosis for many cancer types. However, an accurate technique to noninvasively image EGFR expression in vivo is not available in the clinical setting. In this...
不幸的是，获得性耐药似乎是不可避免的，并限制了 EGFR-TKI 在临床实践中的应用。2022年3月18日，中国药科大学丁选胜及广州医科大学张建业共同通讯在Molecular Cancer（IF=27）在线发表题为“Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression...
NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels cell linescolorectal cancerEGFRNEU3sialylationSeveral studies performed over the last decade have focused on the role of sialylation in the progression of ......
The EGFR protein expression levels and subcellular localisations were examined by two different anti-EGFR antibodies: clone 5B7 against the intracellular domain and clone 3C6 against the extracellular domain, hereafter referred to as intracellular and extracellular domain antibodies, respectively. In ...
Moreover, we have identified nebivolol, a clinically used small molecule inhibitor, that can upregulate FBXL2 expression to inhibit EGFR-driven NSCLC growth. Nebivolol in combination with osimertinib or Grp94-inhibitor-1 exhibits strong inhibitory effects on osimertinib-resistant NSCLC. Together, this ...
[12] Tung JN, Lin PL, Wang YC, et al. PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression. Oncotarget 2017;9:4637-46. [13] Chih-Hsin...